How it works
Easy on patients.
A phase 1 / 2 clinical trial has successfully completed for PRV111 in patients with oral cavity cancer. PRV111 has also been evaluated in several preclinical studies. Local and regional effects of PRV111 are expected to improve tumor resectability, decrease post-operative radiation and chemotherapy, and improve patient survival. In patients with metastatic disease, PRV111 (when combined with standard of care chemo-radiation regimen) can provide improved locoregional control while maintaining a tolerable side effect profile that ultimately improves the quality of life. The team is excited about the successful phase 2 study (~70% tumor reduction in just 1 week) and is preparing for a phase 3 trial of PRV111.